The estimated Net Worth of Sath Shukla is at least $1.71 million dollars as of 27 August 2024. Sath Shukla owns over 2,757 units of Spero Therapeutics Inc stock worth over $1,528,684 and over the last 5 years Sath sold SPRO stock worth over $184,641.
Sign up
Sath Shukla SPRO stock SEC Form 4 insiders trading
Sath has made over 6 trades of the Spero Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Sath sold 2,757 units of SPRO stock worth $3,722 on 27 August 2024.
The largest trade Sath's ever made was selling 75,994 units of Spero Therapeutics Inc stock on 1 February 2024 worth over $107,911. On average, Sath trades about 11,061 units every 61 days since 2019. As of 27 August 2024 Sath still owns at least 1,140,809 units of Spero Therapeutics Inc stock.
You can see the complete history of Sath Shukla stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Sath Shukla's mailing address?
Sath's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Spero Therapeutics Inc
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela et Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
What does Spero Therapeutics Inc do?
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
What does Spero Therapeutics Inc's logo look like?
Complete history of Sath Shukla stock trades at Alaunos Therapeutics Inc et Spero Therapeutics Inc
Spero Therapeutics Inc executives and stock owners
Spero Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ankit Mahadevia,
President, Chief Executive Officer, Director -
Dr. Ankit Mahadevia M.D., MBA,
Co-Founder, CEO, Pres & Director -
Cristina Larkin,
Chief Operating Officer and Chief Commercial Officer -
David Melnick,
Cheif Medical Officer -
Dr. David A. Melnick M.D.,
Chief Medical Officer -
Cristina Larkin,
Chief Operating Officer -
Thomas Parr,
Chief Scientific Officer -
Cynthia Smith,
Independent Director -
Milind Deshpande,
Independent Chairman of the Board -
Frank Thomas,
Independent Director -
Patrick Vink,
Independent Director -
John Pottage,
Independent Director -
Jean-Francois Formela,
Independent Director -
Sharon Klahre,
IR Contact Officer -
Scott Jackson,
Independent Director -
Timothy Keutzer,
Chief Development Officer -
Stephen DiPalma,
Chief Financial Officer, Treasurer -
Timothy Keutzer,
Chief Devel. Officer -
James P. Brady,
Chief Human Resource Officer -
David Musselman,
Sr. VP of Sales & Market Access -
Tamara Lynn Joseph L.L.M., J.D.,
Chief Legal Officer -
Ted Jenkins,
VP & Head of Investor Relations -
Dr. Thomas R. Parr Jr., Ph.D.,
Chief Scientific Officer -
Satyavrat Shukla C.F.A.,
Chief Financial Officer -
David P Southwell,
Director -
John J Gorman,
Director -
Jack Fingerhut,
President -
Allen S Greene,
Chairman of the Board and CEO -
Lager H Martin,
Director -
Joel Sendek,
Chief Financial Officer -
Plc Gsk,
10% owner -
Joseph R Fish,
EVP & Chief Technology Officer -
Leonard J Stanley,
Director -
Vikas Goyal,
Director -
Casper Breum,
Director -
Stanley P Wirtheim,
Chief Financial Officer -
Zohar Ben Dov,
10% owner -
Esther Rajavelu,
See Remarks -
Capital Management, Llc Aqu...,
-
Kathleen Tregoning,
-
Kamal Hamed,
Chief Medical Officer -
Sath Shukla,
CEO & President -
Tamara L Joseph,
Chief Legal Officer